Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 12, 2026Frontiers in Cardiovascular MedicineOpen Access

SGLT2 inhibitors provide cardiovascular protection through interconnected mechanisms including hemodynamic rebalancing and cardiometabolic reprogramming, with robust prognostic benefits in heart failure.

View Full Paper
Ask AI
Bookmark
Share

Design

Review

Key result

SGLT2 inhibitors provide cardiovascular protection through interconnected mechanisms including hemodynamic rebalancing and cardiometabolic reprogramming, with robust prognostic benefits in heart failure.

Authors

ZWZi WangYWYijin WangWSWangning Shangguan

Discussion

Loading...

Member takes

Overview

May support SGLT2 expansion in HFpEF; leaves open optimal patient selection and long-term outcomes.

Key Points

  • This review aims to summarize the cardiovascular and cardiorenal benefits of SGLT2 inhibitors, beyond their glucose-lowering effects.
  • Conducted a narrative review of mechanistic and clinical evidence regarding SGLT2 inhibitors.
  • Analyzed various mechanisms including hemodynamic rebalancing and vascular protection.
  • Examined safety considerations and evolving clinical applications.
  • SGLT2 inhibitors showed significant benefits in heart failure with reduced ejection fraction and retained potential in preserved ejection fraction.
  • Evidence for improvement in NT-proBNP levels and ventricular remodeling in post-myocardial infarction settings was noted.
  • Potential reduction in the risk of atrial fibrillation or flutter emerged but requires dedicated trials.

Structured PICO

I
Intervention
SGLT2 inhibitors as a class (including empagliflozin, dapagliflozin, canagliflozin, ertugliflozin, bexagliflozin)

SGLT2 inhibitors act as cardiovascular-metabolic modulators with robust prognostic benefits in heart failure, driven by pleiotropic mechanisms beyond glucose lowering.

Limitations

  • Much of the current mechanistic evidence is derived from cellular and animal models.
  • It remains uncertain whether different SGLT2 inhibitors exert distinct drug-specific effects across disease contexts.
  • The extent to which individual molecular pathways directly mediate clinical outcome improvements has not been fully established.

Cite This Study

Wang et al. (2026) conducted a review in Cardiovascular disease. SGLT2 inhibitors was evaluated. SGLT2 inhibitors provide cardiovascular protection through interconnected mechanisms including hemodynamic rebalancing and cardiometabolic reprogramming, with robust prognostic benefits in heart failure.

synapsesocial.com/papers/6a2bd1056550ea4541ffe79chttps://doi.org/10.3389/fcvm.2026.1776906
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched one closely related paper. Consider it for comparative context:

  1. 1The Failing Heart — An Engine Out of Fuel2007 · 2,439 citations